Interest in applications of protein crystallography to medicine was evident as the first high-resolution structures emerged in the 50s and 60s. In Cambridge Max Perutz and John Kendrew sought to understand mutations in sickle cell and other genetic diseases related to haemoglobin, while in Oxford the group of Dorothy Hodgkin became interested in long-lasting zinc-insulin crystals for treatment of diabetes and later considered insulin redesign as synthetic insulins became possible. The use of protein crystallography in structure-guided drug discovery emerged as enzyme structures allowed the identification of potential inhibitor-binding sites and optimisation of interactions of hits using the structure of the target protein. Early examples of this approach were the use of the structure of renin to design anti-hypertensives and the structure of HIV protease in design of AIDS antivirals. More recently, use of structure-guided design with fragment-based drug discovery, which reduces the size of screening libraries by decreasing complexity, has improved ligand efficiency in drug design and has been used to progress three oncology drugs through clinical trials to FDA approval. We exemplify current developments in structure-guided target identification and fragment-based lead discovery with efforts to develop new antimicrobials for mycobacterial infections. 
Ideas about drug design were stimulated by the determination of the first enzyme structures -lysozyme, chymotrypsin and trypsin -in the 60s and an emerging understanding of the interactions that led to selectivity of enzyme substrate binding [8] .
In the 70s and 80s, clinically important drug targets such as the aspartic protease renin [9, 10] , which cleaves angiotensinogen to form angiotensin I, an essential step in regulating blood pressure, were modelled on less exciting enzymes such as fungal pepsins [11, 12] . The use of protein crystallography in drug discovery accelerated in the 1980s, especially by using a combination of protein structure and interactive computer graphics, such as the Evans and Sutherland machines [13] . The model of renin [14] was used widely in structure-guided drug design in the pharma industry in the 1980s. The high-resolution X-ray structures of apo-enzymes and complexes of renin and its close homologues followed much later [15, 16] .
New Paradigm of Structure-guided Drug Discovery: Targeting HIV Protease
Probably the most influential development was the design of AIDS antivirals, based on the structure of HIV protease; these moved onto the market very quickly in the 1990s. Some basic science influenced this! In 1978, Jordan Tang who had sequenced pepsin together with crystallographic collaborators suggested that proteases had evolved from an ancestral dimer by gene duplication, fusion and divergence to give more effective enzymes [17] . A close relative of this dimeric ancestral aspartic protease was found in the retroviral proteases, first in Rous Sarcoma Virus, but then in HIV soon after the AIDS epidemic was recognised in the US and Europe. The genome of HIV, which encodes a polyprotein, was shown to include a protease [18] , which was quickly recognised as a dimeric viral protease essential for the generation of infectious viral particles, and a model was produced based on the aspartic proteinase evolutionary relationship [19] . In 1989 structures followed for Rous Sarcoma Virus [20, 21] and HIV protease [22, 23] , the structure of which was improved by further experimental structures determined independently by two labs [24] [25] . The subsequent development of new AIDS antivirals by 1997, including four very successful drugs (Roche Pharmaceuticals' saquinavir, Abbot's ritonavir, Merck's indinavir, and Agouron's nelfinavir) demonstrated the importance of understanding the genome not only in terms of functions of gene products, but also their architectures for use in structure-guided drug discovery, recorded recently in an excellent history of macromolecular crystallography and its fruits [26] A C C E P T E D M A N U S C R I P T
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The identification of HIV protease as a target and the development of AIDS antivirals was a new paradigm in drug discovery. It demonstrated that there was value in computational analysis of genomes in order to identify targets. This was an "exploration of biological space", an exciting challenge in the early 1990s as the sequence determination of human infectious agents such Mycobacteriaceae that give rise to tuberculosis and leprosy, as well as the very much larger genome of Homo sapiens became real prospects. The HIV protease inhibitor story also illustrated the importance "exploring chemical space": using protein structure to estimate the druggability of potential targets, followed by exploration of possible binding using screening libraries of chemical compounds. This idea of drug discovery can be summarised, as in Figure 1A .
Over the subsequent 25 years, several new approaches have been introduced that exploit knowledge of the architecture of the target and screening of chemical libraries.
One of the most influential has been the development of structure-guided fragmentbased drug discovery.
Protein Crystallography, Fragment-Based Drug Discovery and Oncology
In the 1980s and 90s meeting the challenge of the size and diversity of "chemical space" became a focus in the pharmaceutical industry with the realisation that chemical libraries of several thousand drug-like compounds explored only a tiny area of the chemical space. In order to estimate the number, Lipinski rules assuming a molecular weight limit of 500 daltons, the presence of carbon, hydrogen, oxygen, nitrogen and sulfur, and a maximum of 4 rings leads to an estimate of 10 63 [27] . Big pharma searched the world for new chemical diversity, often using the products of our natural environment in underdeveloped-forested areas. The chemical libraries grew to hundreds of thousands of compounds and screening was roboticized to cope with the challenge. But a solution to the challenge was also found in a different approach in which complexity of the chemicals screened was reduced by decreasing their molecular weights, which at the same time increased their promiscuity in binding targets. The innovation that allowed decrease of size of the chemical screening library was fragment-based drug discovery (FBDD).
In FBDD, a fragment library often of ~ 1000 compounds of <300 Da is screened against the target of interest, resulting in identification of initial hits. These are then potency than the more complex molecules found in typical high-throughput screening (HTS) compound libraries, however small fragments that bind, do so by making well defined and directional high-quality interactions and by displacing unhappy water molecules at the hotspots, giving rise to high ligand efficiency [28] .
Early experiments used ligand-based NMR (Steve Fesik and his colleagues at Abbott) [29] and X-ray crystal screening [30, 31] , developed at Astex initially by exploiting high-throughput analysis of cocktails of six to ten fragments soaked into apo-protein crystals. Knowledge of the structure of the complex of the fragment with target protein allowed the initial use of small, often non-chiral compounds, which were optimized using structure-guided approaches to make specific interactions and to introduce chirality in the molecules. The resulting fragment hits were capable of achieving high binding efficiency per atom and often better physicochemical properties in comparison to those from HTS approach which exploits much larger libraries of ~10 6 or more compounds [30, 32] .
The relatively low affinities mean that a combination of biochemical, biophysical and structural techniques must be used to monitor hit identification, validation and subsequent elaboration into lead molecules, as summarised in Figure 1B . The choice of methods will depend on factors such as the availability of a sensitive biochemical assay, the solubility and stability of the protein, the existence of crystals of the apoprotein, and so on. Many groups use a two-stage approach of high-throughput screening of the fragment library using fluorescence-based thermal shift measurements [32, 33] , ligand-based NMR, surface plasmon resonance (SPR) and increasingly with the roboticized screening facilities available on synchrotron beamlines, X-ray crystallographic screening. The fragment hits common between these techniques are then validated by optimisation of resolution of the structures by X-ray diffraction or structure determination by NMR if not possible to define by X-ray methods, as well as defining the kinetics with SPR and the thermodynamics of the binding using isothermal calorimetry. The combination of these techniques and others ( Figure 1B) gives reassurance of the quality of the hit. The validated fragment hits are then elaborated iteratively by growing to a larger molecular weight or by linking using structure-guided techniques.
Where a crystal structure is not available, several labs have used fragment libraries to search chemical space using methods such as SPR [34] , sometimes with many thousands of chiral compounds, often derived from analysis of successful drugs [35] .
Where an experimental structure or computational homology model is available, the pipeline can be complemented by substructure searches on commercially available compound databases or in-silico screening predictions of analogues [36, 37] . An example of this approach was that of Winter et al. [38] , who had no suitable crystal structure to identify hits that disrupt the interaction between hepatocyte growth factor/scatter factor N-terminal fragment and the hepatocyte growth factor receptor (Met), and subsequently inhibit Met signalling. They carried out sub-structure searches on initial hits identified by biophysical methods such as SPR, and followed these by in-silico docking predictions to identify compounds, with significant antitumorigenic and anti-migratory activity in cell-based assays.
In 2011 the first fragment-derived drug, Vemurafenib, was approved targeting a mutant form of BRAF, extending life for patients with skin cancer. The drug was discovered at Plexxikon and developed in partnership with Roche. The second drug, Venetoclax, developed by AbbVie and Genentech, binds to BCL-2 and blocks its interaction with other proteins; was approved by the US FDA in 2016 for chronic lymphocytic leukemia (CLL). In 2017 the third drug, Ribociclib, by Astex and Novartis was approved for targeting the protein kinase Cdk4 and will be used in combination with letrozole as a first-line treatment for advanced breast cancer. All of these campaigns featured an important role for structure-guided approaches with a combination of activity in relatively small companies, often founded by academics with an interest in protein structure, but developed as cancer therapeutics with strong scientific and financial involvement of large pharma.
Moving Structure-guided Discovery from Oncology to other Diseases
We have shown that the HIV protease paradigm exploiting a combination of efficient exploration of biological space by understanding the genome and structural proteome, together with exploration of chemical space using structure-guided and fragmentbased approaches, works well in cancer. As described above, FBDD has not only provided useful leads but also led to drugs that have been approved by the FDA. Much of the work has been done in biotech and small pharma companies in collaboration with large pharma.
We now address the question as to how far this structure-guided approach can be used to target diseases that are rare in the West, where big pharma finds it more difficult to get returns on its investment. These include genetic diseases occurring in a few Here we focus on infectious diseases caused by mycobacteria to illustrate the way that structure-guided lead discovery in academia can use its experience in early lead discovery built on biochemistry, medicinal chemistry and structural biology, together with microbiology and human medicine. We show how knowledge of protein structure is central not only to select targets (exploring biological space) but also to develop new leads (exploring chemical space).
Genomes of Mycobacteriaceae
The Mycobacteriaceae family comprises 174 known species of acid-fast bacteria with high GC content and much thicker hydrophobic outer cell walls (containing mycolic against drug-resistant TB or have toxic side effects due to the required prolonged treatments (up to 24 months), thereby leading to significant morbidity and mortality [40] .
Although previously thought to be benign environmental microbes, Non-Tuberculous mycobacteria (NTM) are increasingly observed over the past decade, as a cause of infections worldwide [41, 42] . This paradigm shift in NTM prevalence is presumably due to higher environmental exposure rates to such mycobacteria, increased selective pressure imparted by intensive antibiotic use in patients, autophagy-inhibitionassociated reduction in host immunity after prolonged antibiotic treatment or patientto-patient transmission [43, 44] . Mab, a distant relative of Mtb and Mlep [45, 46] is a free-living nontuberculous mycobacterium commonly found in water and soil, which causes skin and soft-tissue infections and pulmonary diseases, particularly in patients with lung disease (such as cystic fibrosis) or a previous history of tuberculosis [47, 48] .
A single-centre retrospective study of CF patients showed an increase in incidence of NTM infections from 0 to 9% over a period from 2002 to 2011 [49] . antibiotic-inactivating enzymes, target-modifying enzymes and genes providing metal resistance [52] [53] [54] . Acquired resistance is frequently associated with spontaneous mutations of antibiotic target genes, although alteration in function of one or more other genes may also be involved [52, 53] .
The current clinical management of Mab infection in CF is highly challenging due to the high rates of resistance of the bacterium to antibiotics and most of the classical
anti-tuberculosis drugs [45] . Further, owing to its resistance to most commonly used disinfectants, various outbreaks of Mab infections in clinical and post-surgical settings have been reported [55] . Current treatment involves prolonged therapy using antibiotic combinations such as clarithromycin, amikacin, and cefoxitin, which are often poorly tolerated and lead to toxic side effects [47] . showed inhibitory activity at the cellular level [69, 70] . A high throughput screening of the AstraZeneca compound library and subsequent structure-guided lead optimization led to the development of a set of compounds that significantly reduced the bacterial burden of gram-positive bacteria such as S. pneumoniae and S. aureus both in vitro and in animal models of infection [71] . However, these compounds were not progressed into clinical development owing to unfavorable toxicity and pharmacokinetic profiles.
We have built on the fragment-based drug discovery campaign against Mtb PPAT, which has led to the development of potential lead compounds having binding affinities to Mtb PPAT in the low micromolar range (Jamal, E. B., Blaszczyk, M., 
Fragment Binding & Hotspot Maps
We further analyzed the binding propensities of PPAT protein to ligands with the help of the hotspot-mapping program developed by Radoux and co-workers [81] . Hotspots are often defined as areas within the protein that provide relatively large contributions to the overall binding affinity of ligands [82, 83] . These regions not only satisfy the minimum binding requirement for fragments but also maintain the original fragment binding interactions when elaborated. The importance of hydration thermodynamics is becoming increasingly recognized as a driving force for fragment binding to target proteins [84] . It has been hypothesized that hotspot regions are characterized by the presence of water molecules having restricted translational and rotational freedom owing to their location within a hydrophobic cavity or close to a patchwork of hydrogen bonds and lipophilic amino-acid sidechains. Ligand binding that displaces such water molecules leads to a favorable free-energy change mainly due to an entropic contribution [84] . The hotspot-mapping program identifies interactions that drive fragment binding by a global search of the protein structure, calculating gridbased atomic propensities for specific donor, acceptor and hydrophobic interactions. This is followed by weighting the propensity scores based on buriedness of the grid points and sampling of the weighted atomic scores using three simple molecular probes to create corresponding donor, acceptor and hydrophobic hotspot maps [81] .
While the observed fragment hits satisfy many of the predicted protein-hotspot interactions, the map contoured at a lower level suggests potential ways to elaborate the fragments to reach those hotspot regions that are not yet explored ( Figure 5A ). For example, fragment 2 is found to be mediating the donor and acceptor hotspots via hydrogen bonds to backbone carbonyl of Gly88 by the indazole NH and to active site Ser9 and Phe10 via the carboxylic acid moiety, at sub-pockets I and II respectively.
Similarly, fragment 4 is found to satisfy the predicted H-bond acceptor interactions through the mandelic acid moiety forming H-bond to Ser9 and active site water molecules and the phenoxy group of the fragment making hydrophobic contact to Leu73. These fragments may be further elaborated in the direction of the hotspots corresponding to interactions with Asn105, Thr113 and Glu98 at the base of the active site, as shown in Figure 5A .
'Fragment-like' Drugs against Mycobacterial species
Many critical drugs in current chemotherapy regimen against Mtb are indeed smaller than 'drug-like' having molecular weights in the range of 100-300 daltons. These include anti-tuberculosis drugs like isoniazid (INH), ethionamide (ETH) and paraaminosalicylic acid (PAS), which are still found to be useful against drug-susceptible TB, as well as pyrazinamide (PZA) a key relapse-reducing drug. Though these drugs require fairly long treatment periods and are less effective against drug-resistant Mtb, it is intriguing how these small molecules have retained their killing effect over nearly a century from the time they were developed. Gopal et al [85] Based on this idea, Moreira and co-workers in a recent study [88] identified 38 fragment hits having bactericidal activity against Mtb (MIC 50 < 500 µM), from screening a fragment library of 1725 compounds. Interestingly, 23 out of the 38 identified hits were shown to have bactericidal activity against M. avium and 13 hits against Mab as well. These hits retained their favourable pharmacokinetic properties and a good fraction of the hits were found to be selective against mammalian cells, though no structure-activity relationship could be established.
Fragment-like molecules were found to potentiate the effect of ethionamide (ETH), a second line TB drug, by 10-fold and showed significant intrinsic bactericidal activity in the absence of ethionamide in a study done by Nikiforov and co-workers [89] . Here, Because the fragment-elaboration for the Mab PPAT target is ongoing, we use examples of the fragment-merging approach that was successfully applied in our lab and elsewhere to develop small molecule inhibitors of Mtb.
(i) Fragment merging to develop inhibitors against Mtb EthR.
A fragment-merging approach to develop small molecule inhibitors of Mtb EthR led to the development of a potent lead candidate in a recent study [90] . EthR is a physiological dimer having a large hydrophobic binding cavity but containing a number of H-bond acceptors and aromatic residues capable of directed π interactions; the starting fragments 1 & 2 were each found to occupy two distinct sites thus filling the entire cavity as shown in Figure 6A & B. Merging of Fragments 1 & 2 further resulted in a significantly potent lead molecule, compound 15 ( Figure 6C ) affording an IC 50 of 3μM [90] .
(ii) Fragment elaboration to inhibit a Mtb cytochrome P450 (CYP) enzyme
A fragment elaboration approach by Hudson & co-workers led to the development of high affinity ligands against CYP121, a cytochrome P450 (CYP) enzyme [91] . The mycobacterial genome encodes for at least 20 different CYPs that play an important role in virulence and survival of the bacteria [92] . CYPs belong to a family of monooxygenase enzymes containing heme as a co-factor that catalyze the oxidation of organic molecules and thereby mediate diverse metabolic processes. CYP121 is found exclusively in Mtb and helps in the production of mycocyclosin, a secondary metabolite, by catalyzing the formation of a C-C bond between the two tyrosine residues of the substrate cyclodityrosine (cYY). Rv2276, the gene encoding for CYP121, was found to be an essential Mtb gene, suggesting that the product mycocyclosin has an important cellular role or an overproduction of the substrate cYY is toxic to the organism [93, 94] . A fragment screening approach that combines fluorescence-based thermal shift assay, NMR (STD and WaterLOGSY) and X-ray crystallography helped in the identification of 4 hits from a fragment library of 665 compounds adopting two distinct binding modes [95] .
Elaboration of these fragments hits resulted in several promising derivatives ( Figure   6D ). In particular, the two different binding conformations of fragment 10 (K d =1.7mM) was exploited to synthesize compound 12. Although this was less active than the starting fragment, further replacement of its five-membered ring with an aminopyrazole led to compound 13 with a K d of 40 M. Growth of compound 13 into the water-filled cavity of CYP121 resulted in compound 14, with an additional phenol ring which mediated further H-bonds with the active site water molecules, improving the affinity by over 100-fold from the starting fragment (K d of 15 M,) [91, 95, 96] .
Elaboration of the lead compound 14 by Kavanagh and colleagues and the addition of a 3amino-phenyl group at the meta position of the aromatic ring attached to fivemembered ring, led to compound 15 (K d of 0.015M, LE=0.41), the highest affinity inhibitor of CYP121 to date as shown in Figure 6D [97].
(iii) Inhibiting Mtb Thymidylate kinase
Thymidylate kinase (TMK) is an enzyme that belongs to the DNA synthesis pathways and that produces thymidine 5'-diphosphate using ATP and thymidine 5'-monophosphate. This enzyme is an established drug target and has been the focus for many drug discovery campaigns against different pathogens, in both eukaryotes [98] and prokaryotes, including Mtb [99, 100] and also viruses [101] . The essentiality of this enzyme is established in Mtb and drug discovery efforts with this target identified a number of inhibitors some of them with active in cell based assays. However, the vast majority of the compounds obtained are analogues of thymidine and contain a thymidine moiety [100] . To move away from these scaffolds, Naik and colleagues carried out a fragment screening of TMK, combining biochemical assay and NMR, which resulted in the identification of a 3-cyanopyridone containing fragment for chemical elaboration [102] . The mode of binding of this fragment hit was determined by molecular docking. Subsequent development of the fragment, supported by X-ray crystal structures of key compounds, allowed the development of nanomolar-potency lead compounds against TMK that retained high ligand efficiency. These compounds were found to have different binding modes from the substrate analogues and some were found to inhibit Mtb in whole cell assays.
CONCLUSIONS
The use of protein structure, defined by experimental and computational approaches for renin and HIV protease, developed for target identification, validation and development of new leads in the 1980s and 1990s, has provided a paradigm for use of structural biology to underpin drug discovery. The progress in structure-guided drug discovery has been impressive, but there remain many challenges for the future. They lie not only in more efficient exploration of biological and chemical space at the molecular level, but also in understanding the many aspects of cell and whole organism biology that affect ligand transport, permeability and metabolism, as well as the changes in complex assemblies over space and time.
Progress in defining biological space requires more efficient approaches to improve experimental structures. This may come from X-ray methods using conventional crystallisation techniques and from X-ray small angle scattering. However, some of the most exciting new developments have come from single-particle cryo-EM methods, for example those developed with the new powerful electron microscopes such as the FEI Titan Krios transmission electron microscope (TEM) combined with direct electron detectors [103] , and new software such as RELION [104] , which carries out 2D image classification followed 3D reconstruction. These revolutionary changes have allowed binding of antibiotics to be envisaged on ribosome particles [105] [106] .
This approach will be particularly powerful at defining structures of the complex systems involved in cell regulation and signalling, where interfacial inhibitors or stabilisers are of interest.
Experimental methods of defining biological and chemical space will likely continue to be challenging even for organisms with relatively small genomes. Structures are required to define interactions of macromolecular and small ligands with proteins. The impacts of strain variation, including mutations that are selectively advantageous in evolution as well as disadvantageous in disease, will need to be understood at the level of protein structure. Thus, it is inevitable that computational methods will need to be improved not only to predict the structures and dynamics of monomers and their interactions with small molecules, but also the multicomponent systems often involving proteins that are intrinsically disordered in parts or the whole of their polypeptide chains; these are still very challenging.
As we have seen, fragment-based drug discovery has improved the exploration of chemical space, especially where targets are well described in terms of structure.
Fragments that are stably bound and maintain their positions during elaboration bind at hotspots. Some progress has been made in recognising these from the structure as we have described, for example Radoux et al., 2016 [81] . It is now becoming clear that there is wide range of interaction types in addition to H-bonds and simple lipophilic interactions, including π-π, π-δ-positive and π-δ-negative charge, and these can be displayed using software such as Arpeggio [107] Fragment based approaches can screen a vast chemical space using a relatively small library of fragments with a set of desired physiochemical properties that can be retained and controlled during the structure-guided optimization of the fragment hits.
Finding inhibitors against mycobacteria is a highly challenging task due to the impermeability of cell wall, multidrug efflux-pumps and drug modifying enzymes that these organisms possess. Small hydrophilic molecules are known to cross the mycobacterial cell wall through porins but large macrocycles and small hydrophobic molecules also diffuse through the cell wall, resulting in TB drugs being widely distributed across chemical space [109] . Solving the structure of efflux pumps in these organisms will surely provide insights into the efflux mechanisms and help identify chemical scaffolds that are extruded from cells, thereby allowing FBDD approaches to optimise the chemistry of new lead molecules.
The structure-guided fragment-based approach avoids the requirement for large screening libraries and provides a route to the discovery of new therapeutics for diseases that lead to many deaths throughout the world and gives hope for effective medicines for rare diseases and those that affect the large populations of less affluent parts of the world. Knowledge of protein structure has contributed to the development of early stages of drug discovery and is widely exploited in both industry and academia.
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